InsidersTradesSigma
Follow the Tempus AI, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Tempus AI, Inc. has recorded 269 public disclosures. Market capitalisation: €11.4bn. The latest transaction was filed on 3 September 2026 (Cession). Among the most active insiders: LEFKOFSKY ERIC P. The full history is accessible without an account.
269
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€183m
206 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Tempus AI, Inc. Buy (bullish), based on 14 analysts. Average price target: US$63.36.
48Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,658 of 29,062 companies
29.7
score / 100
Value28
Quality31
FCF yld-2.2%
Earn yld-2.2%
EV/EBITDA·
ROE-67%
Gross mgn63%
Net mgn-19%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations269 total
676 shares@ US$65.55Class A Common StockSEC:0001739090-26-000012:0
250 shares@ US$65.55Class A Common StockSEC:0001445826-26-000012:0
13,046 shares@ US$62.12Class A Common StockSEC:0002024250-26-000035:0
10,900 shares@ US$62.64Class A Common StockSEC:0002024250-26-000035:1
5,900 shares@ US$63.80Class A Common StockSEC:0002024250-26-000035:2
1,000 shares@ US$64.63Class A Common StockSEC:0002024250-26-000035:3
760 shares@ US$64.030.0004% mcap0.1% of flowClass A Common StockSEC:0001114357-26-000034:0
4,218 shares@ US$67.010.0023% mcap0.4% of flowClass A Common StockSEC:0001114357-26-000034:3
5,093 shares@ US$64.700.0027% mcap0.4% of flowClass A Common StockSEC:0001114357-26-000034:9
52,784 shares@ US$68.970.029% mcap4.7% of flowClass A Common StockSEC:0001114357-26-000034:13
284 shares@ US$64.700.0001% mcap0.0% of flowClass A Common StockSEC:0001114357-26-000034:17
1,365 shares@ US$68.130.0007% mcap0.1% of flowClass A Common StockSEC:0001114357-26-000034:20
2,887 shares@ US$68.960.0016% mcap0.3% of flowClass A Common StockSEC:0001114357-26-000034:21
660 shares@ US$64.030.0003% mcap0.1% of flowClass A Common StockSEC:0001114357-26-000034:24
2,168 shares@ US$64.700.0011% mcap0.2% of flowClass A Common StockSEC:0001114357-26-000034:1
3,944 shares@ US$65.980.0021% mcap0.3% of flowClass A Common StockSEC:0001114357-26-000034:2
10,282 shares@ US$68.130.0056% mcap0.9% of flowClass A Common StockSEC:0001114357-26-000034:4
22,495 shares@ US$68.970.013% mcap2.0% of flowClass A Common StockSEC:0001114357-26-000034:5
12,851 shares@ US$69.830.0072% mcap1.2% of flowClass A Common StockSEC:0001114357-26-000034:6
782 shares@ US$70.580.0004% mcap0.1% of flowClass A Common StockSEC:0001114357-26-000034:7
1,789 shares@ US$64.030.0009% mcap0.1% of flowClass A Common StockSEC:0001114357-26-000034:8
9,262 shares@ US$65.980.0049% mcap0.8% of flowClass A Common StockSEC:0001114357-26-000034:10
9,935 shares@ US$67.010.0054% mcap0.9% of flowClass A Common StockSEC:0001114357-26-000034:11
24,161 shares@ US$68.130.013% mcap2.1% of flowClass A Common StockSEC:0001114357-26-000034:12
30,139 shares@ US$69.830.017% mcap2.7% of flowClass A Common StockSEC:0001114357-26-000034:14
25 of 269 declarations
关于 Tempus AI, Inc.
Tempus AI, Inc. 是一家总部位于美国的医疗技术公司，在美国纳斯达克上市，业务涵盖人工智能、基因组学和精准医疗。该公司由 Eric Lefkofsky 于 2015 年在芝加哥创立，其核心理念是，大规模的临床和分子数据可以显著改善治疗决策，最初是在肿瘤学领域，现在正日益扩展到更广泛的疾病领域。Tempus 总部位于伊利诺伊州芝加哥，其商业足迹主要集中在美国，服务于医院、癌症中心、实验室、研究人员和生物制药合作伙伴。 Tempus 的商业模式建立在互补的收入流之上。其诊断部门提供分子和基因组检测，旨在更好地表征肿瘤和其他复杂疾病。与此同时，该公司商业化数据、分析和人工智能工具，帮助用户利用专有的临床和分子数据集进行研究、生物标志物发现、临床试验匹配和决策支持。这种诊断加数据/软件的结构是其与传统实验室检测公司以及缺乏 Tempus 自身数据资产的健康软件供应商的关键区别。 从竞争角度来看，Tempus 旨在成为领先的精准医疗平台。其投资案例基于其数据的规模和质量、检测与软件之间的集成，以及与制药公司、学术机构和卫生系统合作的能力。该公司还一直强调新的支持人工智能的产品和战略合作伙伴关系，以加强其在患者分层、筛查和护理优化方面的地位。 近期里程碑突显了该公司的发展势头。2026 年 5 月 5 日，Tempus 公布 2026 年第一季度收入为 348.1 million 美元，同比增长 36.1%，并强调了多项合作，包括与 Bristol Myers Squibb 和 USC 的合作项目。2026 年 5 月初，Tempus 还宣布发行 400 million 美元可转换优先票据，旨在优化其资本结构并降低利息支出。此外，该公司被《时代》杂志评为 2026 年最具影响力的 10 家健康和生命科学公司之一。对于投资者而言，Tempus 仍然是一家高增长的医疗技术公司，在数据货币化和产品采用方面具有显著的上涨潜力，但也伴随着精准医疗固有的执行、报销、监管和商业化风险。
